---
title: "CSPC Innovation Pharmaceutical Co.,Ltd. (300765.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300765.SZ.md"
symbol: "300765.SZ"
name: "CSPC Innovation Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T10:45:38.582Z"
locales:
  - [en](https://longbridge.com/en/quote/300765.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300765.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300765.SZ.md)
---

# CSPC Innovation Pharmaceutical Co.,Ltd. (300765.SZ)

## Company Overview

CSPC Innovation Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of biopharmaceuticals, functional foods, and raw materials in China and internationally. The company offers functional raw ingredients, including caffeine, acarbose, anhydrous glucose, theophylline, aminophylline, dyphylline, theobromine, pentoxifylline, and doxofylline; and health food products, such as Guoweikang Vitamin C tablets, Guoweikang B vitamin lozenges, etc. It also provides technology transfer and technical consulting services of biotechnology.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.xnwpharma.net](https://www.xnwpharma.net) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.53)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 68 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 21.87% |  |
| Net Profit YoY | -489.78% |  |
| P/B Ratio | 16.30 |  |
| Dividend Ratio | 0.07% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 42072029906.31 |  |
| Revenue | 2354539899.05 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -9.81% | D |
| Profit Margin | -13.11% | D |
| Gross Margin | 41.15% | B |
| Revenue YoY | 21.87% | B |
| Net Profit YoY | -489.78% | E |
| Total Assets YoY | 1.93% | C |
| Net Assets YoY | -38.72% | E |
| Cash Flow Margin | 93.62% | C |
| OCF YoY | 21.87% | B |
| Turnover | 0.38 | C |
| Gearing Ratio | 57.00% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - CSPC Innovation Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "21.87%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-489.78%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "16.30",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.07%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "42072029906.31",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2354539899.05",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-9.81%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-13.11%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "41.15%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "21.87%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-489.78%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.93%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-38.72%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "93.62%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "21.87%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.38",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "57.00%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -136.32 | 215/215 | - | - | - |
| PB | 16.30 | 215/215 | 19.71 | 16.85 | 12.99 |
| PS (TTM) | 17.87 | 205/215 | 37.55 | 26.04 | 21.06 |
| Dividend Yield | 0.07% | 156/215 | 0.06% | 0.05% | 0.04% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-27T16:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 75% |
| Overweight | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 29.52 |
| Highest Target | 61.40 |
| Lowest Target | 41.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300765.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300765.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300765.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300765.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**